148 related articles for article (PubMed ID: 16474376)
1. Study of phospho-beta-catenin subcellular distribution in invasive breast carcinomas in relation to their phenotype and the clinical outcome.
Nakopoulou L; Mylona E; Papadaki I; Kavantzas N; Giannopoulou I; Markaki S; Keramopoulos A
Mod Pathol; 2006 Apr; 19(4):556-63. PubMed ID: 16474376
[TBL] [Abstract][Full Text] [Related]
2. Aberrant expression of β-catenin in invasive ductal breast carcinomas.
Abd El-Rehim D; Ali MM
J Egypt Natl Canc Inst; 2009 Jun; 21(2):185-95. PubMed ID: 21057570
[TBL] [Abstract][Full Text] [Related]
3. Correlation of astrocyte elevated gene-1, basic-fibroblast growth factor, beta-catenin, Ki-67, tumor necrosis factor-alfa with prognostic parameters in ductal carcinomas and ductal intraepithelial neoplasms.
Erdem H; Gundogdu B; Ankarali H; Yasar M; Sener E; Oktay M; Bahadir A; Uzunlar AK; Gursan N; Ozaydin I; Sahiner C
Niger J Clin Pract; 2015; 18(5):638-43. PubMed ID: 26096243
[TBL] [Abstract][Full Text] [Related]
4. Expression of tissue inhibitor of matrix metalloproteinases (TIMP)-3 protein in invasive breast carcinoma: relation to tumor phenotype and clinical outcome.
Mylona E; Magkou C; Giannopoulou I; Agrogiannis G; Markaki S; Keramopoulos A; Nakopoulou L
Breast Cancer Res; 2006; 8(5):R57. PubMed ID: 17032447
[TBL] [Abstract][Full Text] [Related]
5. Tissue microarray analysis of beta-catenin in colorectal cancer shows nuclear phospho-beta-catenin is associated with a better prognosis.
Chung GG; Provost E; Kielhorn EP; Charette LA; Smith BL; Rimm DL
Clin Cancer Res; 2001 Dec; 7(12):4013-20. PubMed ID: 11751495
[TBL] [Abstract][Full Text] [Related]
6. PPARgamma and Wnt/beta-Catenin pathway in human breast cancer: expression pattern, molecular interaction and clinical/prognostic correlations.
Jiang Y; Zou L; Zhang C; He S; Cheng C; Xu J; Lu W; Zhang Y; Zhang H; Wang D; Shen A
J Cancer Res Clin Oncol; 2009 Nov; 135(11):1551-9. PubMed ID: 19495794
[TBL] [Abstract][Full Text] [Related]
7. Study of the topographic distribution of ets-1 protein expression in invasive breast carcinomas in relation to tumor phenotype.
Mylona EE; Alexandrou PT; Giannopoulou IA; Rafailidis PI; Markaki S; Keramopoulos A; Nakopoulou LL
Cancer Detect Prev; 2006; 30(2):111-7. PubMed ID: 16632244
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of p53 and c-erbB-2 expression, proliferative activity and angiogenesis in node-negative breast carcinoma.
Erdem O; Dursun A; Coşkun U; Günel N
Tumori; 2005; 91(1):46-52. PubMed ID: 15850004
[TBL] [Abstract][Full Text] [Related]
9. Wnt signaling pathway in invasive ductal carcinoma of the breast: relationship between beta-catenin, dishevelled and cyclin D1 expression.
Prasad CP; Gupta SD; Rath G; Ralhan R
Oncology; 2007; 73(1-2):112-7. PubMed ID: 18337623
[TBL] [Abstract][Full Text] [Related]
10. Preserved Axin expression is associated with an aggressive phenotype in invasive breast carcinomas.
Irini T; Paraskevi A; Ioanna G; Christos P; Lydia N
APMIS; 2013 Sep; 121(9):797-805. PubMed ID: 23278310
[TBL] [Abstract][Full Text] [Related]
11. c-met tyrosine kinase receptor expression is associated with abnormal beta-catenin expression and favourable prognostic factors in invasive breast carcinoma.
Nakopoulou L; Gakiopoulou H; Keramopoulos A; Giannopoulou I; Athanassiadou P; Mavrommatis J; Davaris PS
Histopathology; 2000 Apr; 36(4):313-25. PubMed ID: 10759945
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of the topographic distribution of uPAR expression in invasive breast carcinomas.
Giannopoulou I; Mylona E; Kapranou A; Mavrommatis J; Markaki S; Zoumbouli Ch; Keramopoulos A; Nakopoulou L
Cancer Lett; 2007 Feb; 246(1-2):262-7. PubMed ID: 17319000
[TBL] [Abstract][Full Text] [Related]
13. MMP-2 protein in invasive breast cancer and the impact of MMP-2/TIMP-2 phenotype on overall survival.
Nakopoulou L; Tsirmpa I; Alexandrou P; Louvrou A; Ampela C; Markaki S; Davaris PS
Breast Cancer Res Treat; 2003 Jan; 77(2):145-55. PubMed ID: 12602913
[TBL] [Abstract][Full Text] [Related]
14. The ductal phenotypic expression of the E-cadherin/catenin complex in tubulolobular carcinoma of the breast: an immunohistochemical and clinicopathologic study.
Esposito NN; Chivukula M; Dabbs DJ
Mod Pathol; 2007 Jan; 20(1):130-8. PubMed ID: 17143261
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical detection of phospho-Akt, phospho-BAD, HER2 and oestrogen receptors alpha and beta in Malaysian breast cancer patients.
Seow HF; Yip WK; Loh HW; Ithnin H; Por P; Rohaizak M
Pathol Oncol Res; 2010 Jun; 16(2):239-48. PubMed ID: 19882362
[TBL] [Abstract][Full Text] [Related]
16. Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients.
López-Knowles E; Zardawi SJ; McNeil CM; Millar EK; Crea P; Musgrove EA; Sutherland RL; O'Toole SA
Cancer Epidemiol Biomarkers Prev; 2010 Jan; 19(1):301-9. PubMed ID: 20056651
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors affecting disease-free survival rate following surgical resection of primary breast cancer.
Horita K; Yamaguchi A; Hirose K; Ishida M; Noriki S; Imamura Y; Fukuda M
Eur J Histochem; 2001; 45(1):73-84. PubMed ID: 11411868
[TBL] [Abstract][Full Text] [Related]
18. Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis.
Vaziri SA; Krumroy LM; Elson P; Budd GT; Darlington G; Myles J; Tubbs RR; Casey G
Clin Cancer Res; 2001 Jul; 7(7):1937-45. PubMed ID: 11448907
[TBL] [Abstract][Full Text] [Related]
19. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
Park SS; Kim SW
Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
[TBL] [Abstract][Full Text] [Related]
20. Abnormal alpha-catenin expression in invasive breast cancer correlates with poor patient survival.
Nakopoulou L; Gakiopoulou-Givalou H; Karayiannakis AJ; Giannopoulou I; Keramopoulos A; Davaris P; Pignatelli M
Histopathology; 2002 Jun; 40(6):536-46. PubMed ID: 12047765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
